Location: Madrid, Spain
Date: September 26 to September 30
European Society for Medical Oncology.
Vemurafenib vs. vemurafenib + cobimetinib in previously untreated BRAFV600–positive advanced melanoma
Neoadjuvant chemo and extrapleural pneumonectomy of malignant pleural mesothelioma +/- hemithoracic radiotherapy: SAKK17/04 trial
ESMO Expert on Lung Cancer: Novelties of ESMO 2104
The IMELDA and TANIA trials
ESMO Expert on Breast Cancer: Breast cancer trial presentations of the congress
ESMO Expert on GI Tumours: Novelties of colorectal cancer treatment
Vemurafenib + cobimetinib in BRAFV600-positive advanced melanoma: the coBRIM trial
Nivolumab vs. chemotherapy in patients with advanced melanoma after prior anti-CTLA-4 therapy: the CHECKMATE 037 trial
ESMO Expert on Lung Cancer: What are the new results in lung cancer treatment?
Professional burnout in European Young Oncologists: a serious risk for doctors and patients alike?
ESMO's tasks and improving cancer drug reimbursement in Europe
ESMO 2014 Highlights: Melanoma and colorectal cancer are the main field of progress
Cancer during pregnancy
Afatinib vs. methotrexate as second-line treatment for rec/met head&neck squamous cell carcinoma
Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the Phase 3 studies ROMANA 1 and 2